In addition, males have presented fewer side effects than females in clinical trials, and two treatment/cancer type combinations drive favourable SOR outcomes in females: EGFR inhibitors in NSCLC and rituximab in NHL (Fig. 1). This evidence concerns the gene EGFR and non-Hodgkin lymphoma.